Ocumetics Technology Corp. ("Ocumetics" or the "Company") (TSV:V OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ...

The TECNIS Odyssey IOL addresses a significant unmet need for cataract patients seeking greater spectacle independence., Bizz ...

Abbott announced that the Food and Drug Administration (FDA) has approved the Tecnis Symfony Intraocular Lenses for the treatment of cataracts. Abbott announced that the Food and Drug Administration ...

FDA Approves Initiation GOLDEN GATE Pivotal Trial Following FDA Breakthrough Device Designation ...

New Alcon Innovations in Intraocular Lenses, Digital Health Solutions to be Showcased at the AAO 2020 Virtual Annual Meeting Pivotal data on the novel AcrySof® IQ Vivity® IOL to be presented ahead of ...

The new full visual range IOL*1 delivers exceptional distance vision2 and 14% smaller readable print size vs PanOptix3 †. 93% of patients become free from glasses at all distances.#4 ‡ TECNIS Odyssey ...

The new approvals are the latest in Johnson & Johnson’s IOLs; the Company claims the new TECNIS Eyhance IOL can slightly extend the depth of focus and deliver better image contrast. The Food and Drug ...

With best-in-class image contrast and low-light performance, TECNIS Odyssey IOL expands the Johnson & Johnson portfolio of ...

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced CE Mark ...

Intraocular lenses (IOLs), implanted in the eye as treatment for cataracts or myopia, are a growing global market in an ageing population, one estimated to be worth more than $4.5 billion by 2022.

LONDON--(BUSINESS WIRE)--Technavio’s latest report on the global intraocular lens (IOLs) market provides an analysis of the most important trends expected to impact the market outlook from 2017-2021.

An expert MD reveals clear insights into cataract surgery, spotlighting the breakthroughs in treatment: "We live in a time of ...